Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
RN

RNXTStockRenovoRx, Inc.

Nasdaq Capital Market · Healthcare · US

$1.10 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment RNXT's does — no target price to set, unlike a price alert.

Stable Ratio screen, 4 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine · assessed 2026-08-29
4 of 7 pass our own screen — the standards disagree
Purification 100.00% *HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure3 of 5 timeframes bullish · 78.3% aligned
VWAPPrice holding above VWAP ($1.06)
VolumeRelative volume 6.7× the 20-day average
Momentum10-day rate of change -13.7%

RenovoRx, Inc. (RNXT) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-08-29). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts

Still fetching analyst coverage — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Momentum (10d)
-13.7%
rate of change
SMC grade
D · 40
78.3% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2026-09-30)
D · 40
SMC grade — 78.3% timeframe alignment
-13.7%
Rate of change (10d)

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to RNXT’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $50.2M as of 2026-11-18.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.71% 30.00% Pass(29.3pp buffer)
Interest-bearing investments 20.73% 30.00% Pass(9.3pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 2.88% 33.00% Pass(30.1pp buffer)
Interest-bearing investments 83.65% 33.00% Fail(50.7pp over)
Non-liquid assets 11.45% at least 20.00% Fail(8.6pp below the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 2.88% 33.33% Pass(30.5pp buffer)
Cash + interest-bearing securities 83.65% 33.33% Fail(50.3pp over)
Accounts receivable 88.55% 33.33% Fail(55.2pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 83.65% 33.33% Fail(50.3pp over)
Accounts receivable 88.55% 50.00% Fail(38.6pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.90% 33.00% Pass(32.1pp buffer)
Cash + interest-bearing securities 26.27% 33.00% Pass(6.7pp buffer)
Accounts receivable 1.54% 33.00% Pass(31.5pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.14% 33.00% Pass(31.9pp buffer)
Cash + interest-bearing securities 33.03% 49.00% Pass(16.0pp buffer)
Accounts receivable 1.93% 49.00% Pass(47.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.14% 33.33% Pass(32.2pp buffer)
Cash + interest-bearing securities 33.03% 33.33% Pass(0.3pp buffer)
Accounts receivable 34.97% 49.00% Pass(14.0pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

MSCI Islamic M-Series (% of 36-mo avg market cap)cash and interest ratio 0.3pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
MSCI Islamic Index (% of total assets)receivables ratio 55.2pts
Usmani (% of total assets)investments ratio 50.7pts
MSCI Islamic Index (% of total assets)cash and interest ratio 50.3pts

The numbers the ratios are built from

Read from RNXT's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $1.1M 2026-09-30 Revenues
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $10.4M 2026-09-30 CashAndCashEquivalentsAtCarryingValue
Total assetsBalance sheet total $12.4M 2026-09-30 Assets
Market capDenominator for AAOIFI $50.2M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $35.0M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $41.8M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2026-09-30 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-05, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-30, period ended 2026-09-30. Screened 2026-11-18.

  • Total assets$12.4M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-05
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30 · no filing link for this figure
  • Cash and interest-bearing securities$10.4M
    CashAndCashEquivalentsAtCarryingValue · period ended 2026-09-30 · 10-Q filed 2026-11-05
  • Receivables$609.0K
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-11-05
  • Revenue$1.1M
    Revenues · period ended 2025-12-31 · 10-K filed 2026-03-30
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2026-09-30 · no filing link for this figure
  • Market cap$50.2M
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link

4 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for RNXT. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for RNXT has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-18.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (0.7% against a 30% line) would only fail if the market cap fell by 98%, to $1.2M.

AAOIFI's investments ratio is $10.4M cash and interest-bearing investments over a market cap of $50.2M (as of 2026-11-18), 20.7% against a 30% line.

It would fail if the market cap fell to $34.7M (-31%), about $0.72 a share against $1.04 implied by the screen's own figures.

AAOIFI would then fail; the majority verdict would stay Not compliant (3 of 7 decided standards passing).

At the screen's market cap, cash and interest-bearing investments would have to rise by $4.7M to reach the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (1 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold RNXT

1 of the 186 funds whose filed holdings we currently hold own RNXT shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns RNXT.

You may already own it

Widely held U.S. index funds. If you own one, you own RNXT through it. None of them is a Shariah fund; the last column is our look-through of each.

FundRNXT in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%

Sorted by RNXT’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names RNXT once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding RNXT
InvestorFirmPositionWeightAs of
Peter Brown Renaissance Technologies $2M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

2.522.071.631.180.732025-11-182026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
0.88
S2
0.92
S1
0.98
PIVOT
1.02
R1
1.08
R2
1.12
R3
1.18

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
1.20 – 2.12
±27.88% from 1.66, made 2026-09-25 · resolves 2026-10-02
BUY
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)42.90NEUTRAL
Stochastic %K (14)34.33NEUTRAL
CCI (20)-79.22NEUTRAL
Williams %R (14)-65.67NEUTRAL
MACD (12,26,9)-0.01SELL
ROC (10)-15.27SELL
Momentum (10)-0.20SELL
EMA (10)1.12SELL
SMA (10)1.12SELL
EMA (20)1.19SELL
SMA (20)1.23SELL
EMA (30)1.24SELL
SMA (30)1.22SELL
EMA (50)1.29SELL
SMA (50)1.38SELL
EMA (100)1.27SELL
SMA (100)1.30SELL
EMA (200)1.15SELL
SMA (200)1.11SELL

About RenovoRx, Inc.

Healthcare · Biotechnology

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

renovorx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 64
⏰ 4H BULLISH 32
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-13.7%
Rate of change (10d)
6.7×
Volume vs its 20-day average
-0.09
MACD (no fresh cross)
$1.13
Volume POC (today)
$1.11 – $1.14
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.